Online Trading Community for Traders and Investors!
CEPH Cephalon beats by $0.43, beats on revs; guides Q3 and FY10 EPS above consensus;
Reports Q2 (Jun) earnings of $2.20 per share, excluding non-recurring items, $0.43 better than the Thomson Reuters consensus of $1.77; revenues rose 32.7% year/year to $726.9 mln vs the $693.9 mln consensus. Co issues mixed guidance for Q3, sees EPS of $1.80-1.90, excluding non-recurring items, vs. $1.76 Thomson Reuters consensus; sees Q3 revs of $670-700 mln vs. $712.37 mln Thomson Reuters consensus. Co issues mixed guidance for FY10, sees EPS of $7.45-7.65, excluding non-recurring items, vs. $6.92 Thomson Reuters consensus; sees FY10 revs of $2.63-2.71 bln vs. $2.73 bln Thomson Reuters consensus. Q2 sales for Provigil of $284 mln vs. analyst estimates of $290 mln; reported Q2 sales for Treanda of $99.7 mln vs. analyst estimates of $91 mln.
Comment
© 2013 Created by StockMarketFunding.com.
You need to be a member of "Daily Stock Charts" Stock Market Trading Community for Traders to add comments!
Join "Daily Stock Charts" Stock Market Trading Community for Traders